Engineering the true potential of CRISPR

Emendo is focused on bringing innovation to disease indications where there has been little to no progress. We tackle the “incurable” with our CRISPR-based technology platform to bring to bear the highest precision in gene editing to treat the most challenging diseases.

Our novel approach to engineering nucleases creates a custom fit design for each disease, allowing us to achieve single-allele editing strategies for the severest indications, such as Severe Congenital Neutropenia (SCN), a debilitating disease caused by mutations in the neutrophil elastase gene ELANE. Our successful knockdown of the single ELANE allele for SCN demonstrates the incredible therapeutic potential of Emendo’s approach, opening up a wide range of options for gene editing therapies where traditional CRISPR nucleases have previously been ineffective.